Merck’s head of IR departs to take up finance chief role at SQZ Biotech
Teri Loxam is leaving her role as head of IR at Merck to become the chief financial officer at SQZ Biotechnologies, a private firm focused on developing cell therapies to treat a range of diseases.
As Merck’s senior vice president of IR and global communications, Loxam had a wide remit overseeing the pharmaceutical company’s IR, PR, media relations and internal communications. Prior to Merck, she spent three years at IMAX as vice president of IR – during which time she helped the company’s China business list in Hong Kong.
Earlier in her career, Loxam worked for 11 years at biopharmaceutical company Bristol-Myers Squibb, where she held roles in strategic planning, portfolio management, treasury and investor relations.
‘We are thrilled to welcome Teri to the SQZ team and believe that her leadership skills and diversified expertise in healthcare strategy, treasury and finance will be essential as we continue to grow SQZ and develop as a company,’ says Armon Sharei, founder and CEO of the biotech firm, in a company statement.
‘The SQZ platform has the potential to transform the cell therapy space and joining the company at this exciting time is an incredible opportunity,’ adds Loxam in the statement. ‘I look forward to working with the dynamic team and contributing to SQZ’s future success as we continue to develop transformational cell therapies for patients.’
With Loxam moving on, Merck have promoted Peter Dannenbaum to the position of vice president of IR, effective August 19, 2019.
A member of the IR team since 2017, Dannenbaum previously worked as a portfolio manager focused on the healthcare sector at CDPQ New York, part of Canadian institutional investor Caisse de dépôt et placement du Québec. Before that, he held analyst and portfolio manager roles at Morgan Stanley Investment Management and John A Levin & Company.